vimarsana.com
Home
Live Updates
Relapsed DLBCL: Complete Interim Response, SCT Beats CAR T : vimarsana.com
Relapsed DLBCL: Complete Interim Response, SCT Beats CAR T
'In patients with relapsed DLBCL in a complete remission, treatment with auto-HCT is associated with a lower rate of relapse/progression, and a longer progression-free survival [versus CAR T therapy].'
Related Keywords
San Diego
,
California
,
United States
,
New York
,
University Of Rochester
,
American
,
Morphosys Incyte
,
Mazyar Shadman
,
Jonathanw Friedberg
,
Bristol Myers Squibb
,
American Society Of Hematology
,
International Blood Marrow Transplant Research
,
Division Of Medical Oncology
,
Wilmot Cancer Institute
,
University Of Washington
,
Astrazeneca
,
Genentech
,
Medical Oncology
,
American Society
,
International Blood
,
Marrow Transplant Research
,
Samuel Durand Professor
,
Fate Therapeutics
,
Mustang Bio
,
Non Hodgkin Amp 039s Lymphoma
,
Non Hodgkin Lymphoma
,
Hl
,
Biologic Therapy
,
Iologics
,
Chimeric Antigen Receptort Cell Therapy
,
Chimeric Antigen Receptors
,
Himeric Immunoreceptors
,
Himerict Cell Receptors
,
Rtificialt Cell Receptors
,
Art Chimaeric Antigen Receptort Cell Therapy Receptors Immunoreceptors Chimaerict
,
Remission
,
vimarsana.com © 2020. All Rights Reserved.